Incyte Company Insiders
| INCY Stock | USD 70.39 0.66 0.93% |
Incyte's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Incyte suggests that vertually all insiders are panicking. Incyte employs about 2.5 K people. The company is managed by 15 executives with a total tenure of roughly 37 years, averaging almost 2.0 years of service per executive, having 168.27 employees per reported executive.
| Herve Hoppenot Chairman Chairman, CEO and President and Member of Non-Management Stock Option Committee |
| Dashyant Dhanak President Executive Vice President Chief Scientific Officer |
Incyte's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-11-06 | Barry P Flannelly | Disposed 3680 @ 79.68 | View | ||
| 2024-09-12 | Thomas Tray | Disposed 572 @ 62.94 | View | ||
| 2024-07-25 | Vijay K Iyengar | Disposed 15571 @ 70 | View | ||
| 2024-07-16 | Barry P Flannelly | Disposed 1306 @ 64.19 | View | ||
| 2024-07-09 | Barry P Flannelly | Disposed 8148 @ 60 | View | ||
| 2024-06-12 | Barry P Flannelly | Disposed 19164 @ 60 | View | ||
| 2024-06-06 | Thomas Tray | Disposed 1093 @ 58.91 | View | ||
| 2024-01-02 | Vijay K Iyengar | Disposed 657 @ 65 | View | ||
| 2023-12-12 | Thomas Tray | Disposed 210 @ 57.36 | View |
Monitoring Incyte's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Incyte |
Incyte's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Incyte's future performance. Based on our forecasts, it is anticipated that Incyte will maintain a workforce of slightly above 2520 employees by December 2024.Incyte's latest congressional trading
Congressional trading in companies like Incyte, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Incyte by those in governmental positions are based on the same information available to the general public.
Incyte Management Team Effectiveness
Return On Tangible Assets is likely to rise to 0.1 in 2024. Return On Capital Employed is likely to rise to 0.12 in 2024. At this time, Incyte's Return On Assets are fairly stable compared to the past year. Incyte's management efficiency ratios could be used to measure how well Incyte manages its routine affairs as well as how well it operates its assets and liabilities.Net Income Applicable To Common Shares is likely to rise to about 411.3 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 130.7 M in 2024.
Incyte Workforce Comparison
Incyte is rated third overall in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 28,422. Incyte holds roughly 2,524 in number of employees claiming about 9% of equities under Health Care industry.
Incyte Profit Margins
The company has Profit Margin (PM) of 0.01 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.15 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.15.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 1.39 | 0.931 |
|
|
Incyte Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Incyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Incyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Incyte insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 0.6 | 3 | 5 | 30,127 | 9,496 |
| 2024-09-01 | 1.0435 | 24 | 23 | 369,851 | 133,639 |
| 2024-06-01 | 3.8333 | 23 | 6 | 157,488 | 5,495,192 |
| 2024-03-01 | 1.6923 | 22 | 13 | 365,599 | 13,969 |
| 2023-12-01 | 3.0 | 6 | 2 | 57,196 | 1,277 |
| 2023-09-01 | 2.1818 | 24 | 11 | 384,297 | 121,892 |
| 2023-06-01 | 23.0 | 23 | 1 | 486,704 | 488.00 |
| 2023-03-01 | 1.5172 | 44 | 29 | 640,732 | 174,322 |
| 2022-12-01 | 1.375 | 11 | 8 | 31,800 | 33,080 |
| 2022-09-01 | 2.5833 | 31 | 12 | 488,400 | 51,293 |
| 2022-06-01 | 3.375 | 27 | 8 | 154,531 | 97,862 |
| 2022-03-01 | 1.2115 | 63 | 52 | 2,997,451 | 163,447 |
| 2021-12-01 | 8.75 | 35 | 4 | 1,654,880 | 40,922 |
| 2021-09-01 | 1.3043 | 30 | 23 | 330,904 | 44,409 |
| 2021-06-01 | 1.8571 | 26 | 14 | 117,314 | 151,855 |
| 2021-03-01 | 1.5 | 36 | 24 | 328,638 | 86,177 |
| 2020-12-01 | 1.6 | 24 | 15 | 43,669 | 50,513 |
| 2020-09-01 | 0.7833 | 47 | 60 | 453,228 | 373,078 |
| 2020-06-01 | 1.1778 | 53 | 45 | 513,941 | 675,777 |
| 2020-03-01 | 2.0 | 42 | 21 | 416,657 | 98,078 |
| 2019-12-01 | 0.8261 | 38 | 46 | 220,080 | 320,762 |
| 2019-09-01 | 0.8974 | 35 | 39 | 420,487 | 240,307 |
| 2019-06-01 | 2.0 | 30 | 15 | 558,215 | 2,336,252 |
| 2019-03-01 | 1.5333 | 46 | 30 | 748,814 | 279,133 |
| 2018-12-01 | 3.0 | 15 | 5 | 133,508 | 41,000 |
| 2018-09-01 | 1.0417 | 25 | 24 | 312,576 | 69,822 |
| 2018-06-01 | 4.1429 | 29 | 7 | 429,184 | 213,900 |
| 2018-03-01 | 2.0 | 28 | 14 | 316,713 | 72,451 |
| 2017-12-01 | 2.0 | 8 | 4 | 34,924 | 37,031 |
| 2017-09-01 | 1.3421 | 51 | 38 | 334,454 | 165,514 |
| 2017-06-01 | 1.0244 | 42 | 41 | 333,705 | 305,463 |
| 2017-03-01 | 2.2 | 44 | 20 | 11,154,265 | 12,024,815 |
| 2016-12-01 | 1.1818 | 13 | 11 | 57,166 | 114,541 |
| 2016-09-01 | 6.6 | 33 | 5 | 357,642 | 170,000 |
| 2016-06-01 | 4.2 | 21 | 5 | 238,737 | 50,311 |
| 2016-03-01 | 11.3333 | 136 | 12 | 5,264,802 | 117,540 |
| 2015-12-01 | 1.0 | 25 | 25 | 250,589 | 523,842 |
| 2015-09-01 | 0.963 | 26 | 27 | 4,744,907 | 1,127,784 |
| 2015-06-01 | 0.5679 | 46 | 81 | 681,153 | 1,064,321 |
| 2015-03-01 | 1.0114 | 89 | 88 | 981,102 | 1,253,112 |
| 2014-12-01 | 0.625 | 25 | 40 | 363,661 | 773,825 |
| 2014-09-01 | 0.6667 | 12 | 18 | 57,333 | 114,666 |
| 2014-06-01 | 0.9565 | 22 | 23 | 232,777 | 242,612 |
| 2014-03-01 | 1.1667 | 42 | 36 | 1,394,115 | 1,487,263 |
| 2013-12-01 | 2.1 | 21 | 10 | 533,545,000 | 117,407,000 |
| 2013-09-01 | 0.5 | 5 | 10 | 161,244 | 375,522 |
| 2013-06-01 | 1.7143 | 12 | 7 | 220,000 | 175,699 |
| 2013-03-01 | 1.5 | 15 | 10 | 705,006 | 360,163 |
| 2012-12-01 | 3.0 | 3 | 1 | 345,000 | 50,000 |
| 2012-09-01 | 0.4444 | 4 | 9 | 92,366 | 164,732 |
| 2012-06-01 | 1.0 | 18 | 18 | 312,389 | 410,754 |
| 2012-03-01 | 1.8667 | 28 | 15 | 1,062,864 | 135,000 |
| 2011-06-01 | 0.1327 | 13 | 98 | 371,664 | 567,007 |
| 2011-03-01 | 0.5625 | 18 | 32 | 808,367 | 527,843 |
| 2010-06-01 | 7.0 | 21 | 3 | 342,251 | 195,834 |
| 2010-03-01 | 5.5 | 11 | 2 | 394,000 | 40,000 |
| 2009-09-01 | 0.7273 | 8 | 11 | 162,000,000 | 97,717,353 |
| 2009-03-01 | 6.4545 | 71 | 11 | 47,561,303 | 343,750 |
| 2007-12-01 | 51.3333 | 154 | 3 | 3,569,164 | 48,654 |
| 2007-03-01 | 3.0 | 6 | 2 | 240,000 | 39,206 |
| 2006-06-01 | 5.0 | 10 | 2 | 9,478,937 | 530,235 |
| 2005-06-01 | 0.75 | 6 | 8 | 120,000 | 5,103,500 |
| 2004-03-01 | 0.2692 | 7 | 26 | 122,000 | 0.00 |
Incyte Notable Stakeholders
An Incyte stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Incyte often face trade-offs trying to please all of them. Incyte's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Incyte's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Herve Hoppenot | Chairman, CEO and President and Member of Non-Management Stock Option Committee | Profile | |
| Dashyant Dhanak | Executive Vice President Chief Scientific Officer | Profile | |
| Christiana MBA | Executive CFO | Profile | |
| Sheila JD | General VP | Profile | |
| Thomas Tray | Chief Finance | Profile | |
| Pamela Murphy | Vice Communications | Profile | |
| Paula Swain | Executive Resources | Profile | |
| Christine Chiou | Head Relations | Profile | |
| Michael Morrissey | Executive Operations | Profile | |
| PharmD MBA | Executive America | Profile | |
| Steven MD | Executive Officer | Profile | |
| Maria JD | Gen VP | Profile | |
| MBA MBA | Ex America | Profile | |
| Ben Strain | Head Relations | Profile | |
| Sheila Denton | Executive Counsel | Profile |
About Incyte Management Performance
The success or failure of an entity such as Incyte often depends on how effective the management is. Incyte management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Incyte management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Incyte management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.09 | 0.10 | |
| Return On Capital Employed | 0.11 | 0.12 | |
| Return On Assets | 0.09 | 0.09 | |
| Return On Equity | 0.12 | 0.19 |
Please note, the imprecision that can be found in Incyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Incyte. Check Incyte's Beneish M Score to see the likelihood of Incyte's management manipulating its earnings.
Incyte Workforce Analysis
Traditionally, organizations such as Incyte use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Incyte within its industry.Incyte Manpower Efficiency
Return on Incyte Manpower
| Revenue Per Employee | 1.5M | |
| Revenue Per Executive | 246.4M | |
| Net Income Per Employee | 236.8K | |
| Net Income Per Executive | 39.8M | |
| Working Capital Per Employee | 1.3M | |
| Working Capital Per Executive | 227M |
Additional Tools for Incyte Stock Analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.